Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response

Thushangi N. Pathiraja, Vered Stearns, Steffi Oesterreich

Research output: Contribution to journalArticle

Abstract

Recent advances in breast cancer treatment have allowed increasing numbers of patients with estrogen receptor (ER) positive (+) breast cancer to receive various forms of endocrine therapy. Unfortunately, de novo and acquired resistance to endocrine therapy remains a major challenge in the clinic. A number of possible mechanisms for drug resistance have been described, which include activation of growth factor receptor pathways, overexpression of ER coactivators, and metabolic resistance due to polymorphisms in metabolizing enzymes. While many of these changes are caused by genetic alterations, there is also increasing evidence to implicate epigenetic gene regulatory mechanisms in the development of endocrine resistance. Since epigenetic modifications are easier to reverse than genetic mutations, they are appealing therapeutic targets, and thus future improvements in medical care for breast cancer patients will depend upon a better understanding of the roles epigenetic modifications play in endocrine resistance. In this review we will focus on recent advances made in the understanding of epigenetic gene regulation in estrogen response and endocrine resistance in breast cancer. We will also summarize current clinical-translational advances in epigenetic therapy, and discuss potential future clinical use of epigenetic changes as therapeutic targets, especially with respect to endocrine treatment.

Original languageEnglish (US)
Pages (from-to)35-47
Number of pages13
JournalJournal of Mammary Gland Biology and Neoplasia
Volume15
Issue number1
DOIs
StatePublished - Mar 2010

Fingerprint

Epigenomics
Estrogen Receptors
Breast Neoplasms
Therapeutics
Reverse Genetics
Growth Factor Receptors
Regulator Genes
Drug Resistance
Estrogens
Mutation
Enzymes
Genes

Keywords

  • Antiestrogen
  • Breast cancer
  • Epigenetics
  • Estrogen
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response. / Pathiraja, Thushangi N.; Stearns, Vered; Oesterreich, Steffi.

In: Journal of Mammary Gland Biology and Neoplasia, Vol. 15, No. 1, 03.2010, p. 35-47.

Research output: Contribution to journalArticle

@article{4e0e90a1e2ab4225a7ca45c30bd3e97d,
title = "Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response",
abstract = "Recent advances in breast cancer treatment have allowed increasing numbers of patients with estrogen receptor (ER) positive (+) breast cancer to receive various forms of endocrine therapy. Unfortunately, de novo and acquired resistance to endocrine therapy remains a major challenge in the clinic. A number of possible mechanisms for drug resistance have been described, which include activation of growth factor receptor pathways, overexpression of ER coactivators, and metabolic resistance due to polymorphisms in metabolizing enzymes. While many of these changes are caused by genetic alterations, there is also increasing evidence to implicate epigenetic gene regulatory mechanisms in the development of endocrine resistance. Since epigenetic modifications are easier to reverse than genetic mutations, they are appealing therapeutic targets, and thus future improvements in medical care for breast cancer patients will depend upon a better understanding of the roles epigenetic modifications play in endocrine resistance. In this review we will focus on recent advances made in the understanding of epigenetic gene regulation in estrogen response and endocrine resistance in breast cancer. We will also summarize current clinical-translational advances in epigenetic therapy, and discuss potential future clinical use of epigenetic changes as therapeutic targets, especially with respect to endocrine treatment.",
keywords = "Antiestrogen, Breast cancer, Epigenetics, Estrogen, Tamoxifen",
author = "Pathiraja, {Thushangi N.} and Vered Stearns and Steffi Oesterreich",
year = "2010",
month = "3",
doi = "10.1007/s10911-010-9166-0",
language = "English (US)",
volume = "15",
pages = "35--47",
journal = "Journal of Mammary Gland Biology and Neoplasia",
issn = "1083-3021",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response

AU - Pathiraja, Thushangi N.

AU - Stearns, Vered

AU - Oesterreich, Steffi

PY - 2010/3

Y1 - 2010/3

N2 - Recent advances in breast cancer treatment have allowed increasing numbers of patients with estrogen receptor (ER) positive (+) breast cancer to receive various forms of endocrine therapy. Unfortunately, de novo and acquired resistance to endocrine therapy remains a major challenge in the clinic. A number of possible mechanisms for drug resistance have been described, which include activation of growth factor receptor pathways, overexpression of ER coactivators, and metabolic resistance due to polymorphisms in metabolizing enzymes. While many of these changes are caused by genetic alterations, there is also increasing evidence to implicate epigenetic gene regulatory mechanisms in the development of endocrine resistance. Since epigenetic modifications are easier to reverse than genetic mutations, they are appealing therapeutic targets, and thus future improvements in medical care for breast cancer patients will depend upon a better understanding of the roles epigenetic modifications play in endocrine resistance. In this review we will focus on recent advances made in the understanding of epigenetic gene regulation in estrogen response and endocrine resistance in breast cancer. We will also summarize current clinical-translational advances in epigenetic therapy, and discuss potential future clinical use of epigenetic changes as therapeutic targets, especially with respect to endocrine treatment.

AB - Recent advances in breast cancer treatment have allowed increasing numbers of patients with estrogen receptor (ER) positive (+) breast cancer to receive various forms of endocrine therapy. Unfortunately, de novo and acquired resistance to endocrine therapy remains a major challenge in the clinic. A number of possible mechanisms for drug resistance have been described, which include activation of growth factor receptor pathways, overexpression of ER coactivators, and metabolic resistance due to polymorphisms in metabolizing enzymes. While many of these changes are caused by genetic alterations, there is also increasing evidence to implicate epigenetic gene regulatory mechanisms in the development of endocrine resistance. Since epigenetic modifications are easier to reverse than genetic mutations, they are appealing therapeutic targets, and thus future improvements in medical care for breast cancer patients will depend upon a better understanding of the roles epigenetic modifications play in endocrine resistance. In this review we will focus on recent advances made in the understanding of epigenetic gene regulation in estrogen response and endocrine resistance in breast cancer. We will also summarize current clinical-translational advances in epigenetic therapy, and discuss potential future clinical use of epigenetic changes as therapeutic targets, especially with respect to endocrine treatment.

KW - Antiestrogen

KW - Breast cancer

KW - Epigenetics

KW - Estrogen

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=77149122714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149122714&partnerID=8YFLogxK

U2 - 10.1007/s10911-010-9166-0

DO - 10.1007/s10911-010-9166-0

M3 - Article

C2 - 20101445

AN - SCOPUS:77149122714

VL - 15

SP - 35

EP - 47

JO - Journal of Mammary Gland Biology and Neoplasia

JF - Journal of Mammary Gland Biology and Neoplasia

SN - 1083-3021

IS - 1

ER -